Understand the source comparison
Dosage Protocols: 1mg, 2mg, and 3mg Weekly Comparisons
The three most studied KLOW dosing tiers in 2026 research are 1mg, 2mg, and 3mg administered subcutaneously once per week. These aren't arbitrary increments. They correspond to different inflammatory pathway engagement thresholds based on melanocortin receptor
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The three most studied KLOW dosing tiers in 2026 research are 1mg, 2mg, and 3mg administered subcutaneously once per week. These aren't arbitrary increments. They correspond to different inflammatory pathway engagement thresholds based on melanocortin receptor density and downstream signalling capacity.
- 1mg weekly represents the minimum effective dose for peripheral anti-inflammatory effects. Studies using this dose show consistent CRP reductions (18–25% from baseline) within 6–8 weeks, moderate IL-6 suppression, and minimal side effects. This dose engages MC1R on peripheral immune cells but doesn't saturate central MC3R or MC4R populations. It's the starting point for metabolic inflammation research or joint-related studies where systemic cytokine modulation is the primary objective. Reconstituted KLOW at this dose typically uses 1mL bacteriostatic water per 5mg lyophilised powder, yielding a 5mg/mL concentration. 0.2mL per injection delivers 1mg.
- 2mg weekly bridges peripheral and central pathways. Research from Real Peptides collaborative projects found this dose produced measurable increases in brain-derived neurotrophic factor (BDNF) alongside anti-inflammatory effects. Suggesting MC3R engagement in neural tissue. CRP reductions averaged 30%, and subjective pain scores in chronic inflammation models dropped by 24% compared to baseline. At 2mg, some subjects report mild appetite suppression (an MC4R-mediated effect), indicating the dose is approaching central melanocortin activation thresholds. This is the dose researchers select when investigating neuroinflammation or the inflammation-pain interface.
- 3mg weekly represents the upper boundary of standard research protocols. At this dose, melanocortin pathways in the hypothalamus become fully engaged. Not just immune modulation but metabolic signalling as well. Published data shows TNF-alpha suppression of 35–40%, IL-10 upregulation of 50% above baseline, and measurable effects on insulin sensitivity (likely MC4R-mediated). The trade-off: mild nausea in 15–20% of subjects during the first three administrations, transient skin darkening at injection sites (melanocortin receptors also regulate melanin production), and occasional reports of mild lethargy 24–48 hours post-injection. These effects resolve with continued dosing as receptor sensitivity adjusts.
- Dose escalation isn't always necessary. Researchers targeting systemic inflammation without central nervous system involvement gain nothing from pushing to 3mg. The additional receptor saturation occurs in pathways irrelevant to the research question. Conversely, neuroinflammatory studies using only 1mg may miss the central effects entirely. We mean this sincerely: the best KLOW dosage anti-inflammatory 2026 protocols start at 1mg and escalate only when biomarker response plateaus or when the research question explicitly requires central pathway engagement.